GlassScriptPhysician profile
James L Ruble
NPI 1346256260
$605.74
in general payments reported to CMS, 2019-2025
17 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2023: $45.51 · 2024: $177 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $109.84 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $97.47 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $54.98 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $51.40 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $36.63 | 2019-2024 | Trintellix |
| Novo Nordisk INC | $35.08 | 2024-2025 | Wegovy |
| Glaxosmithkline, LLC. | $31.71 | 2019 | |
| Shire North American Group INC | $30.00 | 2019 | |
| Abbvie INC. | $29.89 | 2025 | |
| Axsome Therapeutics, INC. | $25.76 | 2023 | Auvelity |
| Astellas Pharma US INC | $17.61 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $16.54 | 2019 | |
| Horizon Therapeutics Plc | $16.50 | 2019 | |
| Merck Sharp & Dohme LLC | $15.51 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2025 | Zoryve |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $12.01 | 2019 | |
| Pfizer INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ruble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.